|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ,
Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et
al: Rethinking ovarian cancer II: Reducing mortality from
high-grade serous ovarian cancer. Nat Rev Cancer. 15:668–679. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bell D, Berchuck A, Birrer M, Chien J,
Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, et al Cancer
Genome Atlas Research Network: Integrated genomic analyses of
ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
|
|
5
|
Gelmon KA, Tischkowitz M, Mackay H,
Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M,
Gilks B, et al: Olaparib in patients with recurrent high-grade
serous or poorly differentiated ovarian carcinoma or
triple-negative breast cancer: A phase 2, multicentre, open-label,
non-randomised study. Lancet Oncol. 12:852–861. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim G, Ison G, McKee AE, Zhang H, Tang S,
Gwise T, Sridhara R, Lee E, Tzou A, Philip R, et al: FDA Approval
Summary: Olaparib monotherapy in patients with deleterious germline
BRCA-mutated advanced ovarian cancer treated with three or more
lines of chemotherapy. Clin Cancer Res. 21:4257–4261. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Parkes EE and Kennedy RD: Clinical
application of poly(ADP-ribose) polymerase inhibitors in high-grade
serous ovarian cancer. Oncologist. 21:586–593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Murai J, Huang SY, Renaud A, Zhang Y, Ji
J, Takeda S, Morris J, Teicher B, Doroshow JH and Pommier Y:
Stereospecific PARP trapping by BMN 673 and comparison with
olaparib and rucaparib. Mol Cancer Ther. 13:433–443. 2014.
View Article : Google Scholar :
|
|
9
|
Aredia F and Scovassi AI:
Poly(ADP-ribose): A signaling molecule in different paradigms of
cell death. Biochem Pharmacol. 92:157–163. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Delbridge AR, Grabow S, Strasser A and
Vaux DL: Thirty years of BCL-2: Translating cell death discoveries
into novel cancer therapies. Nat Rev Cancer. 16:99–109. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Williams J, Lucas PC, Griffith KA, Choi M,
Fogoros S, Hu YY and Liu JR: Expression of Bcl-xL in ovarian
carcinoma is associated with chemoresistance and recurrent disease.
Gynecol Oncol. 96:287–295. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wong M, Tan N, Zha J, Peale FV, Yue P,
Fairbrother WJ and Belmont LD: Navitoclax (ABT-263) reduces
Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol
Cancer Ther. 11:1026–1035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Witham J, Valenti MR, De-Haven-Brandon AK,
Vidot S, Eccles SA, Kaye SB and Richardson A: The Bcl-2/Bcl-XL
family inhibitor ABT-737 sensitizes ovarian cancer cells to
carboplatin. Clin Cancer Res. 13:7191–7198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rudin CM, Hann CL, Garon EB, Ribeiro de
Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D,
Ramalingam SS, et al: Phase II study of single-agent navitoclax
(ABT-263) and biomarker correlates in patients with relapsed small
cell lung cancer. Clin Cancer Res. 18:3163–3169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roberts AW, Seymour JF, Brown JR, Wierda
WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, et al:
Substantial susceptibility of chronic lymphocytic leukemia to BCL2
inhibition: Results of a phase I study of navitoclax in patients
with relapsed or refractory disease. J Clin Oncol. 30:488–496.
2012. View Article : Google Scholar
|
|
16
|
Domcke S, Sinha R, Levine DA, Sander C and
Schultz N: Evaluating cell lines as tumour models by comparison of
genomic profiles. Nat Commun. 4:21262013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lorenzi PL, Reinhold WC, Varma S,
Hutchinson AA, Pommier Y, Chanock SJ and Weinstein JN: DNA
fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther.
8:713–724. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Prichard MN and Shipman C Jr: A
three-dimensional model to analyze drug-drug interactions.
Antiviral Res. 14:181–205. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Prichard MK, Aseltine KR and Shipman C Jr:
MacSynergy II, version 1.0. User's manual. University of Michigan;
Ann Arbor, MI: 1993
|
|
21
|
Oeck S, Malewicz NM, Hurst S, Rudner J and
Jendrossek V: The Focinator - a new open-source tool for
high-throughput foci evaluation of DNA damage. Radiat Oncol.
10:1632015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao L, Wientjes MG and Au JL-S:
Evaluation of combination chemotherapy: Integration of nonlinear
regression, curve shift, isobologram, and combination index
analyses. Clin Cancer Res. 10:7994–8004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herriott A, Tudhope SJ, Junge G, Rodrigues
N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole
M, et al: PARP1 expression, activity and ex vivo sensitivity to the
PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic
leukaemia. Oncotarget. 6:43978–43991. 2015.PubMed/NCBI
|
|
25
|
Smith MA and Houghton P: A proposal
regarding reporting of in vitro testing results. Clin Cancer Res.
19:2828–2833. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wilson WH, O'Connor OA, Czuczman MS,
LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong
H, Chiu YL, et al: Navitoclax, a targeted high-affinity inhibitor
of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study
of safety, pharmacokinetics, pharmacodynamics, and antitumour
activity. Lancet Oncol. 11:1149–1159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
De Bono JSML, Gonzalez M, Curtin NJ, Wang
E, Henshaw JW, Chadha M, Sachdev JC, Matei D, Jameson GS, Ong M, et
al: First-in-human trial of novel oral PARP inhibitor BMN 673 in
patients with solid tumors. J Clin Oncol. 31:25802013.
|
|
28
|
Shen Y, Rehman FL, Feng Y, Boshuizen J,
Bajrami I, Elliott R, Wang B, Lord CJ, Post LE and Ashworth A: BMN
673, a novel and highly potent PARP1/2 inhibitor for the treatment
of human cancers with DNA repair deficiency. Clin Cancer Res.
19:5003–5015. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan N, Wong M, Nannini MA, Hong R, Lee LB,
Price S, Williams K, Savy PP, Yue P, Sampath D, et al: Bcl-2/Bcl-xL
inhibition increases the efficacy of MEK inhibition alone and in
combination with PI3 kinase inhibition in lung and pancreatic tumor
models. Mol Cancer Ther. 12:853–864. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Green MM, Shekhar TM and Hawkins CJ: Data
on the DNA damaging and mutagenic potential of the BH3-mimetics
ABT-263/Navitoclax and TW-37. Data Brief. 6:710–714. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stamelos VA, Redman CW and Richardson A:
Understanding sensitivity to BH3 mimetics: ABT-737 as a case study
to foresee the complexities of personalized medicine. J Mol Signal.
7:122012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H, Yang YB, Shen HM, Gu J, Li T and
Li XM: ABT-737 induces Bim expression via JNK signaling pathway and
its effect on the radiation sensitivity of HeLa cells. PLoS One.
7:e524832012. View Article : Google Scholar
|
|
33
|
Wang B, Ni Z, Dai X, Qin L, Li X, Xu L,
Lian J and He F: The Bcl-2/xL inhibitor ABT-263 increases the
stability of Mcl-1 mRNA and protein in hepatocellular carcinoma
cells. Mol Cancer. 13:982014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hiraki M, Suzuki Y, Alam M, Hinohara K,
Hasegawa M, Jin C, Kharbanda S and Kufe D: MUC1-C stabilizes MCL-1
in the oxidative stress response of triple-negative breast cancer
cells to BCL-2 inhibitors. Sci Rep. 6:266432016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morales AA, Kurtoglu M, Matulis SM, Liu J,
Siefker D, Gutman DM, Kaufman JL, Lee KP, Lonial S and Boise LH:
Distribution of Bim determines Mcl-1 dependence or codependence
with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood.
118:1329–1339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamaguchi R, Janssen E, Perkins G,
Ellisman M, Kitada S and Reed JC: Efficient elimination of cancer
cells by deoxyglucose-ABT-263/737 combination therapy. PLoS One.
6:e241022011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan
JA, Tammareddi A, Moore VG, Deng J, Anderson KC, Richardson P, Tai
YT, et al: Pretreatment mitochondrial priming correlates with
clinical response to cytotoxic chemotherapy. Science.
334:1129–1133. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lopez J and Tait SW: Mitochondrial
apoptosis: Killing cancer using the enemy within. Br J Cancer.
112:957–962. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Slee EA, Keogh SA and Martin SJ: Cleavage
of BID during cytotoxic drug and UV radiation-induced apoptosis
occurs downstream of the point of Bcl-2 action and is catalysed by
caspase-3: A potential feedback loop for amplification of
apop-tosis-associated mitochondrial cytochrome c release. Cell
Death Differ. 7:556–565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee JM, Hays JL, Annunziata CM, Noonan AM,
Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, et al:
Phase I Ib study of olaparib and carboplatin in BRCA1 or BRCA2
mutation-associated breast or ovarian cancer with biomarker
analyses. J Natl Cancer Inst. 106:dju0892014. View Article : Google Scholar
|
|
41
|
Oza AM, Cibula D, Benzaquen AO, Poole C,
Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H,
et al: Olaparib combined with chemotherapy for recurrent
platinum-sensitive ovarian cancer: A randomised phase 2 trial.
Lancet Oncol. 16:87–97. 2015. View Article : Google Scholar
|
